291 related articles for article (PubMed ID: 27827301)
1. Validation and development of MTH1 inhibitors for treatment of cancer.
Warpman Berglund U; Sanjiv K; Gad H; Kalderén C; Koolmeister T; Pham T; Gokturk C; Jafari R; Maddalo G; Seashore-Ludlow B; Chernobrovkin A; Manoilov A; Pateras IS; Rasti A; Jemth AS; Almlöf I; Loseva O; Visnes T; Einarsdottir BO; Gaugaz FZ; Saleh A; Platzack B; Wallner OA; Vallin KS; Henriksson M; Wakchaure P; Borhade S; Herr P; Kallberg Y; Baranczewski P; Homan EJ; Wiita E; Nagpal V; Meijer T; Schipper N; Rudd SG; Bräutigam L; Lindqvist A; Filppula A; Lee TC; Artursson P; Nilsson JA; Gorgoulis VG; Lehtiö J; Zubarev RA; Scobie M; Helleday T
Ann Oncol; 2016 Dec; 27(12):2275-2283. PubMed ID: 27827301
[TBL] [Abstract][Full Text] [Related]
2. TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model.
Moukengue B; Brown HK; Charrier C; Battaglia S; Baud'huin M; Quillard T; Pham TM; Pateras IS; Gorgoulis VG; Helleday T; Heymann D; Berglund UW; Ory B; Lamoureux F
EBioMedicine; 2020 Mar; 53():102704. PubMed ID: 32151797
[TBL] [Abstract][Full Text] [Related]
3. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool.
Gad H; Koolmeister T; Jemth AS; Eshtad S; Jacques SA; Ström CE; Svensson LM; Schultz N; Lundbäck T; Einarsdottir BO; Saleh A; Göktürk C; Baranczewski P; Svensson R; Berntsson RP; Gustafsson R; Strömberg K; Sanjiv K; Jacques-Cordonnier MC; Desroses M; Gustavsson AL; Olofsson R; Johansson F; Homan EJ; Loseva O; Bräutigam L; Johansson L; Höglund A; Hagenkort A; Pham T; Altun M; Gaugaz FZ; Vikingsson S; Evers B; Henriksson M; Vallin KS; Wallner OA; Hammarström LG; Wiita E; Almlöf I; Kalderén C; Axelsson H; Djureinovic T; Puigvert JC; Häggblad M; Jeppsson F; Martens U; Lundin C; Lundgren B; Granelli I; Jensen AJ; Artursson P; Nilsson JA; Stenmark P; Scobie M; Berglund UW; Helleday T
Nature; 2014 Apr; 508(7495):215-21. PubMed ID: 24695224
[TBL] [Abstract][Full Text] [Related]
4. AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma.
Das I; Gad H; Bräutigam L; Pudelko L; Tuominen R; Höiom V; Almlöf I; Rajagopal V; Hansson J; Helleday T; Egyházi Brage S; Warpman Berglund U
Cell Death Differ; 2020 Jul; 27(7):2081-2098. PubMed ID: 31919461
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B Virus X Protein Increases 8-Oxo-7,8-Dihydro-2'-Deoxyguanosine (8-Oxodg) Level via Repressing MTH1/ MTH2 Expression in Hepatocytes.
Lin YT; Liu W; He Y; Wu YL; Chen WN; Lin XJ; Lin X
Cell Physiol Biochem; 2018; 51(1):80-96. PubMed ID: 30448843
[TBL] [Abstract][Full Text] [Related]
6. Proteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer cell survival.
Kawamura T; Kawatani M; Muroi M; Kondoh Y; Futamura Y; Aono H; Tanaka M; Honda K; Osada H
Sci Rep; 2016 May; 6():26521. PubMed ID: 27210421
[TBL] [Abstract][Full Text] [Related]
7. Potent and specific MTH1 inhibitors targeting gastric cancer.
Zhou W; Ma L; Yang J; Qiao H; Li L; Guo Q; Ma J; Zhao L; Wang J; Jiang G; Wan X; Adam Goscinski M; Ding L; Zheng Y; Li W; Liu H; Suo Z; Zhao W
Cell Death Dis; 2019 Jun; 10(6):434. PubMed ID: 31164636
[TBL] [Abstract][Full Text] [Related]
8. MTH1 Inhibitor TH588 Disturbs Mitotic Progression and Induces Mitosis-Dependent Accumulation of Genomic 8-oxodG.
Rudd SG; Gad H; Sanjiv K; Amaral N; Hagenkort A; Groth P; Ström CE; Mortusewicz O; Berglund UW; Helleday T
Cancer Res; 2020 Sep; 80(17):3530-3541. PubMed ID: 32312836
[TBL] [Abstract][Full Text] [Related]
9. MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good?
Abbas HHK; Alhamoudi KMH; Evans MD; Jones GDD; Foster SS
BMC Cancer; 2018 Apr; 18(1):423. PubMed ID: 29661172
[TBL] [Abstract][Full Text] [Related]
10. Mitotic MTH1 Inhibitors in Treatment of Cancer.
Helleday T
Cancer Treat Res; 2023; 186():223-237. PubMed ID: 37978139
[TBL] [Abstract][Full Text] [Related]
11. The presumed MTH1-inhibitor TH588 sensitizes colorectal carcinoma cells to ionizing radiation in hypoxia.
Pompsch M; Vogel J; Classen F; Kranz P; Iliakis G; Riffkin H; Brockmeier U; Metzen E
BMC Cancer; 2018 Nov; 18(1):1190. PubMed ID: 30497423
[TBL] [Abstract][Full Text] [Related]
12. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy.
Huber KV; Salah E; Radic B; Gridling M; Elkins JM; Stukalov A; Jemth AS; Göktürk C; Sanjiv K; Strömberg K; Pham T; Berglund UW; Colinge J; Bennett KL; Loizou JI; Helleday T; Knapp S; Superti-Furga G
Nature; 2014 Apr; 508(7495):222-7. PubMed ID: 24695225
[TBL] [Abstract][Full Text] [Related]
13. Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma.
Oksvold MP; Berglund UW; Gad H; Bai B; Stokke T; Rein ID; Pham T; Sanjiv K; Øy GF; Norum JH; Smeland EB; Myklebust JH; Helleday T; Våtsveen TK
Sci Rep; 2021 Mar; 11(1):6317. PubMed ID: 33737576
[TBL] [Abstract][Full Text] [Related]
14. MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia.
Sanjiv K; Calderón-Montaño JM; Pham TM; Erkers T; Tsuber V; Almlöf I; Höglund A; Heshmati Y; Seashore-Ludlow B; Nagesh Danda A; Gad H; Wiita E; Göktürk C; Rasti A; Friedrich S; Centio A; Estruch M; Våtsveen TK; Struyf N; Visnes T; Scobie M; Koolmeister T; Henriksson M; Wallner O; Sandvall T; Lehmann S; Theilgaard-Mönch K; Garnett MJ; Östling P; Walfridsson J; Helleday T; Warpman Berglund U
Cancer Res; 2021 Nov; 81(22):5733-5744. PubMed ID: 34593524
[TBL] [Abstract][Full Text] [Related]
15. Delivery of MTH1 inhibitor (TH287) and MDR1 siRNA via hyaluronic acid-based mesoporous silica nanoparticles for oral cancers treatment.
Shi XL; Li Y; Zhao LM; Su LW; Ding G
Colloids Surf B Biointerfaces; 2019 Jan; 173():599-606. PubMed ID: 30352381
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of MutT homolog-1 expression on esophageal squamous cell carcinoma.
Akiyama S; Saeki H; Nakashima Y; Iimori M; Kitao H; Oki E; Oda Y; Nakabeppu Y; Kakeji Y; Maehara Y
Cancer Med; 2017 Jan; 6(1):258-266. PubMed ID: 27917618
[TBL] [Abstract][Full Text] [Related]
17. Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer Target.
Ellermann M; Eheim A; Rahm F; Viklund J; Guenther J; Andersson M; Ericsson U; Forsblom R; Ginman T; Lindström J; Silvander C; Trésaugues L; Giese A; Bunse S; Neuhaus R; Weiske J; Quanz M; Glasauer A; Nowak-Reppel K; Bader B; Irlbacher H; Meyer H; Queisser N; Bauser M; Haegebarth A; Gorjánácz M
ACS Chem Biol; 2017 Aug; 12(8):1986-1992. PubMed ID: 28679043
[TBL] [Abstract][Full Text] [Related]
18. Adaptation to Chronic-Cycling Hypoxia Renders Cancer Cells Resistant to MTH1-Inhibitor Treatment Which Can Be Counteracted by Glutathione Depletion.
Hansel C; Hlouschek J; Xiang K; Melnikova M; Thomale J; Helleday T; Jendrossek V; Matschke J
Cells; 2021 Nov; 10(11):. PubMed ID: 34831264
[TBL] [Abstract][Full Text] [Related]
19. Inhibitor development of MTH1 via high-throughput screening with fragment based library and MTH1 substrate binding cavity.
Peng C; Li YH; Yu CW; Cheng ZH; Liu JR; Hsu JL; Hsin LW; Huang CT; Juan HF; Chern JW; Cheng YS
Bioorg Chem; 2021 May; 110():104813. PubMed ID: 33774493
[TBL] [Abstract][Full Text] [Related]
20. Identification of potent and selective MTH1 inhibitors.
Petrocchi A; Leo E; Reyna NJ; Hamilton MM; Shi X; Parker CA; Mseeh F; Bardenhagen JP; Leonard P; Cross JB; Huang S; Jiang Y; Cardozo M; Draetta G; Marszalek JR; Toniatti C; Jones P; Lewis RT
Bioorg Med Chem Lett; 2016 Mar; 26(6):1503-1507. PubMed ID: 26898335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
